Takeda Pharmaceutical Company Limited (TAK) Stock Price

18.51 ▼ -0.39 (-2.06%)
Open: 18.56 Vol: 2.42M Day's range: 18.3701 - 18.575 Sep 29, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
TAK Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY SELL SELL NEUTRAL BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 18.51▲ 18.51▲ 18.51▲ 18.73▼ 18.60▼
MA10 18.51▲ 18.49▲ 18.61▼ 18.81▼ 18.14▲
MA20 18.52▲ 18.63▼ 18.73▼ 18.61▼ 17.22▲
MA50 18.50▲ 18.70▼ 18.79▼ 17.97▲ 16.70▲
MA100 18.57▼ 18.80▼ 18.70▼ 17.06▲ 15.52▲
MA200 18.71▼ 18.68▼ 18.48▲ 17.11▲ 15.18▲
  5 mins 30 mins Hourly Daily Weekly
MACD -0.003▼ -0.002▼ -0.030▼ -0.047▼ 0.155▲
RSI 53.899▲ 37.872▼ 37.667▼ 51.550▲ 62.176▲
STOCH 44.444     70.669     21.318     51.821     84.861▲
WILL %R -25.000     -72.477     -76.000▼ -59.000     -18.070▲
CCI -32.558     3.880     -57.212     -75.226     83.155    
Latest Filters Detected On TAK
MA $TAK Price Crossed Below MA(13) Set Alert
MA $TAK Price Crossed Below MA(7) Set Alert
CDL $TAK Hammer Candlestick Pattern Detected Set Alert
Takeda Pharmaceutical Company Limited News
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a ...
Tuesday, September 29, 2026 10:00 PM
Takeda (TSE:4502/NYSE:TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine ...
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
Tuesday, September 22, 2026 02:30 AM
Takeda (TSE:4502/NYSE:TAK) announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, ...
Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?
Thursday, September 17, 2026 05:30 AM
Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority review for adults with moderate-to-severe ...
TAK historical stock data
date open high low close volume
29/09/26 18.56 18.575 18.3701 18.51 2,415,171
28/09/26 18.76 19.00 18.645 18.90 2,063,035
25/09/26 18.82 18.91 18.765 18.86 2,737,923
24/09/26 18.55 18.735 18.51 18.59 2,896,244
23/09/26 18.86 18.98 18.78 18.81 2,563,774
22/09/26 18.92 19.045 18.81 18.95 1,403,870
21/09/26 18.98 18.99 18.84 18.89 1,756,150
18/09/26 18.80 19.01 18.80 18.91 2,960,710
17/09/26 19.02 19.10 19.00 19.05 2,708,774
16/09/26 18.75 18.825 18.595 18.64 2,952,150
Quote Details
52wk Low:12.99
52wk High:19.10
Vol:2.42M
Avg Vol(3m):61.6M
1Y Chng:+33.55%
1M Chng:+2.55%
Add to Watch List
More Information
Index N/A
Market Cap. 60.36B